FDA approval for GSK, Roche drugs could boost balance sheets

09/17/2008 | Reuters

The FDA is set to hand down by Friday its decisions on GlaxoSmithKline's Promacta and Roche Holding's Actemra, a move that may boost the drugmakers' market shares. Citigroup analysts estimated that by 2012, Promacta -- a drug to treat a rare blood disorder -- could generate $509.6 million, while Actemra -- a rheumatoid arthritis medicine -- could bring in $638 million.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ